Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in
near-vision restoration, announced that it will be participating at the
13thAegean Cornea Conference to be held in Crete. Vladimir
Feingold, Presbia's Chief Technology Officer and a Presbia board member,
will be conducting a presentation about the Presbia Flexivue Microlens™,
a proprietary optical lens implant that is an innovative solution for
treating the loss of near-vision. The Aegean Cornea Conference, attended
by world-wide leading anterior segment surgeons, will be held on July 1st
through 3rd at Avra Imperial Hotel. Presbia is a sponsor of
"This gathering of prominent surgeons from across the globe will further
the awareness of our groundbreaking Microlens implant as a safe,
effective, and easy to implement treatment for near-vision restoration
that reduces the need for reading glasses," said Todd Cooper, President
and CEO of Presbia. "While we have approvals to commercialize our
Microlens in dozens of countries worldwide, we're taking a
highly-focused approach in our commercialization strategy by continuing
to lay the groundwork in Europe, predominately Germany, our next
targeted area, and are underway in Asia-Pacific with an increasing
presence in South Korea."
This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements.
Such forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the information
included in this press release. Statements made in this press release
that are forward-looking in nature may involve risks and uncertainties,
including, but not limited to, the factors listed under "Risk Factors"
in our annual report on Form 10-K and quarterly reports on Form 10-Q.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Although
Presbia believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may prove to
have been materially different from the results expressed or implied by
such forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any such
risks or uncertainties or to announce publicly the result of any
revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the presbyopia-correcting Presbia
Flexivue Microlens™, a miniature lens that is implanted in a corneal
pocket created by a femtosecond laser. The Presbia Flexivue Microlens™
has received a CE mark for the European Economic Area, allowing the lens
to be marketed in over 30 countries across Europe. A staged pivotal U.S.
clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160630006439/en/
Monica Yamada, 323-860-4903
Source: Presbia PLC
News Provided by Acquire Media